Nishihara K, Miyatake S, Sakata T, Yamashita J, Kikuchi H, Kawade Y, Zu Y, Namba Y, Hanaoka M, Watanabe Y
Department of Neurosurgery, Medical School, Kyoto University, Japan.
Cancer Res. 1988 Sep 1;48(17):4730-5.
As an initial approach to experiments directed toward effective adoptive immunotherapy for cancer using lymphokine genes, we transferred retrovirally a complementary DNA encoding mouse gamma-interferon (IFN-gamma) into a specific cytotoxic T-lymphocyte clone, designated E-4, against 203 glioma cells (a 20-methylcholanthrene-induced mouse glioma line) and confirmed the efficacy of IFN-gamma production from the exogenous gene on augmentation of tumor targeting. Of five, two gene-transferred subclones constitutively produced 8 to 10 times the amount of IFN-gamma as compared with the parental E-4. Correspondingly, these two subclones exhibited 2 to 3 times higher killing activity against 203 glioma than the parental cells; the enhancement of the killing activities was abrogated by an adequate addition of anti-IFN-gamma antibody. No alteration was seen after the gene transfer in cell surface phenotypes, Thy-1+, Lyt-1-, Lyt-2+,3+, and asialo-GM1-. The surface expression of a major histocompatibility complex Class I antigen, H-2Kb, was not altered remarkably, but the Class II antigen, I-Ab, was partially and slightly enhanced on the two IFN-gamma-producing sublines mentioned above on fluorescence-activated cell sorter analysis. Since it is considered that in the vicinity of the constitutively IFN-gamma producing cytotoxic T-lymphocyte cells tumor cells are exposed to a high concentration of IFN-gamma, the cells may be stimulated to induce or enhance the expression of surface antigens including major histocompatibility complex antigens as well as tumor-associated antigens relevant to immune recognition. The 203 glioma cells pretreated with IFN-gamma were more efficiently killed by both the parental E-4 and the gene-transferred sublines. Taken together, the results suggested that the augmented specific tumor-killing activity of our gene-transferred cytotoxic T-lymphocytes was ascribed to the constitutive production of IFN-gamma derived from the exogenous gene.
作为利用淋巴因子基因进行癌症有效过继性免疫疗法实验的初步方法,我们通过逆转录病毒将编码小鼠γ干扰素(IFN-γ)的互补DNA转移到一个针对203胶质瘤细胞(一种20-甲基胆蒽诱导的小鼠胶质瘤细胞系)的特异性细胞毒性T淋巴细胞克隆(命名为E-4)中,并证实了外源基因产生的IFN-γ对增强肿瘤靶向作用的效果。在五个基因转移亚克隆中,有两个亚克隆组成性产生的IFN-γ量比亲本E-4高8至10倍。相应地,这两个亚克隆对203胶质瘤的杀伤活性比亲本细胞高2至3倍;加入适量的抗IFN-γ抗体可消除杀伤活性的增强。基因转移后,细胞表面表型Thy-1 +、Lyt-1 -、Lyt-2 +、3 +和无唾液酸GM1 -未见改变。主要组织相容性复合体I类抗原H-2Kb的表面表达没有明显改变,但在上述两个产生IFN-γ的亚系上,II类抗原I-Ab在荧光激活细胞分选分析中略有部分增强。由于认为在组成性产生IFN-γ的细胞毒性T淋巴细胞细胞附近,肿瘤细胞会暴露于高浓度的IFN-γ中,这些细胞可能会被刺激诱导或增强包括主要组织相容性复合体抗原以及与免疫识别相关的肿瘤相关抗原在内的表面抗原的表达。用IFN-γ预处理的203胶质瘤细胞被亲本E-4和基因转移亚系更有效地杀伤。综上所述,结果表明我们的基因转移细胞毒性T淋巴细胞增强的特异性肿瘤杀伤活性归因于外源基因组成性产生的IFN-γ。